Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Adaptive Stereotactic Radiotherapy With Superparamagnetic Iron Oxide Nanoparticles (SPION) Cellular Magnetic Resonance Imaging on MR-Linac (MR-L-SPION) for Primary and Metastatic Hepatic Malignancies With Assessment of Treatment Response.

NCT04682847 is registered in ClinicalTrials.gov with Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) as lead sponsor.

NCT NCT04682847
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04682847 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Adaptive Stereotactic Radiotherapy With Superparamagnetic Iron Oxide Nanoparticles (SPION) Cellular Magnetic Resonance Imaging on MR-Linac (MR-L-SPION) for Primary and Metastatic Hepatic Malignancies With Assessment of Treatment Response.
Lead sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Phase
Observational
Overall status
Unknown status
Start date
November 19, 2020
Completion date
December 31, 2024
Enrollment
40 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatic atrophy, hepatic carcinoma, hepatic cirrhosis, hepatocellular cancer, hepatocellular carcinoma, liver cancer, liver carcinoma, liver metastases, liver neoplasms